<code id='7AF4785420'></code><style id='7AF4785420'></style>

<acronym id='7AF4785420'></acronym>

<center id='7AF4785420'><center id='7AF4785420'><tfoot id='7AF4785420'></tfoot></center><abbr id='7AF4785420'><dir id='7AF4785420'><tfoot id='7AF4785420'></tfoot><noframes id='7AF4785420'>

<optgroup id='7AF4785420'><strike id='7AF4785420'><sup id='7AF4785420'></sup></strike><code id='7AF4785420'></code></optgroup>

<b id='7AF4785420'><label id='7AF4785420'><select id='7AF4785420'><dt id='7AF4785420'><span id='7AF4785420'></span></dt></select></label></b><u id='7AF4785420'></u>

~~<i id='7AF4785420'><strike id='7AF4785420'><tt id='7AF4785420'><pre id='7AF4785420'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

knowledge

author：focus 2025-08-15 09:11:54 Page View：69

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

advertisement

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why do women spend more than men on medical expenses?
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

ScientistFengZhang,right,isinterviewedbyreporterMeganMolteniatSTAT'sBreakthroughSummitEast.STATWhent

Dobbs anniversary: the lost opportunity of abortion as health care

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Isthereacureforallergies?HastheFDAbecometooflexible?Andwhichdrugsmakeyoumuscular?Wecoverallthatandmo

read more